Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
Bionano Genomics (BNGO) has adjourned its Special Meeting of Stockholders to November 27, 2024, due to insufficient quorum. Only 30.7% of total shares were voted, falling short of the required 33.3% quorum. Of the votes submitted, 76.3% were in favor of the proposal regarding the issuance of common stock upon warrant exercise.
The voting polls will remain open until November 26, 2024. CEO Erik Holmlin emphasized the need for approximately 2.2 million additional votes to reach quorum, warning that failure to approve the proposal could adversely affect the company's ability to raise capital and impact its viability.
Bionano Genomics (BNGO) ha rinviato la sua Assemblea Straordinaria degli Azionisti al 27 novembre 2024, a causa di un quoro insufficiente. Solo il 30,7% delle azioni totali ha votato, non raggiungendo il quoro richiesto del 33,3%. Dei voti espressi, il 76,3% era a favore della proposta riguardante l'emissione di azioni ordinarie in seguito all'esercizio del warrant.
I seggi per il voto rimarranno aperti fino al 26 novembre 2024. Il CEO Erik Holmlin ha sottolineato la necessità di circa 2,2 milioni di voti aggiuntivi per raggiungere il quoro, avvertendo che il mancato approvazione della proposta potrebbe influire negativamente sulla capacità dell'azienda di raccogliere capitali e sulla sua sostenibilità.
Bionano Genomics (BNGO) ha pospuesto su Asamblea Especial de Accionistas para el 27 de noviembre de 2024, debido a la falta de quórum. Solo el 30,7% de las acciones totales votaron, quedando por debajo del quórum requerido del 33,3%. Del total de votos emitidos, el 76,3% fue a favor de la propuesta sobre la emisión de acciones comunes al ejercer la opción.
Las urnas de votación permanecerán abiertas hasta el 26 de noviembre de 2024. El CEO Erik Holmlin enfatizó la necesidad de aproximadamente 2,2 millones de votos adicionales para alcanzar el quórum, advirtiendo que la falta de aprobación de la propuesta podría afectar negativamente la capacidad de la empresa para recaudar capital y su viabilidad.
Bionano Genomics (BNGO)는 불충분한 정족수로 인해 주주 특별회의를 2024년 11월 27일로 연기했습니다. 총 주식의 30.7%만 투표에 참여하여 요구된 33.3%의 정족수에 미치지 못했습니다. 제출된 표 중 76.3%가 보통주 발행 제안에 찬성했습니다.
투표소는 2024년 11월 26일까지 열려 있습니다. CEO Erik Holmlin은 정족수에 도달하기 위해 약 220만 표가 추가로 필요하다고 강조하며, 제안이 승인되지 않을 경우 회사의 자본 조달 능력과 생존성에 부정적인 영향을 줄 수 있다고 경고했습니다.
Bionano Genomics (BNGO) a reporté sa réunion extraordinaire des actionnaires au 27 novembre 2024 en raison d'un quorum insuffisant. Seuls 30,7% des actions totales ont voté, n'atteignant pas le quorum requis de 33,3%. Parmi les votes exprimés, 76,3% étaient en faveur de la proposition concernant l'émission d'actions ordinaires lors de l'exercice des bons de souscription.
Les bureaux de vote resteront ouverts jusqu'au 26 novembre 2024. Le PDG Erik Holmlin a souligné la nécessité d'environ 2,2 millions de votes supplémentaires pour atteindre le quorum, avertissant que le refus d'approuver la proposition pourrait nuire à la capacité de l'entreprise à lever des fonds et à sa viabilité.
Bionano Genomics (BNGO) hat seine außerordentliche Hauptversammlung auf den 27. November 2024 verschoben, da der erforderliche Quorum nicht erreicht wurde. Nur 30,7% der Gesamtanteile haben abgestimmt, was unter dem benötigten Quorum von 33,3% lag. Von den abgegebenen Stimmen stimmten 76,3% für den Vorschlag zur Ausgabe von Stammaktien bei Ausübung der Warrants.
Die Abstimmung bleibt bis zum 26. November 2024 geöffnet. CEO Erik Holmlin betonte die Notwendigkeit von etwa 2,2 Millionen zusätzlichen Stimmen, um das Quorum zu erreichen, und warnte, dass die Ablehnung des Vorschlags negative Auswirkungen auf die Fähigkeit des Unternehmens zur Kapitalbeschaffung und auf seine Lebensfähigkeit haben könnte.
- 76.3% of submitted votes support the warrant exercise proposal
- Failed to reach quorum requirement of 33.3%, with only 30.7% of shares voted
- Potential risk to company's ability to raise future capital if proposal isn't approved
- Risk of impairment to company operations and viability without stockholder approval
Insights
The continued inability to reach quorum for this critical stockholder vote raises significant concerns. With only
Special Meeting of Stockholders Adjourned Due to Lack of Quorum
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it adjourned its reconvened Special Meeting of Stockholders originally held on October 2, 2024 and subsequently adjourned to October 30, 2024 (the “Special Meeting”) because a quorum was not present at the time of the reconvened meeting. Based on preliminary reports as of October 30, 2024, approximately
The Special Meeting will reconvene at 10 a.m. Pacific Time on November 27, 2024. Voting polls will remain open until 11:59 p.m. Eastern Time on November 26, 2024. Proxies previously submitted in respect of the Special Meeting will be voted at the reconvened Special Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.
Stockholders of record may vote their shares by calling Toll-Free at 1-800-690-6903. Further information on the company’s proxy proposal soliciting stockholder approval for the issuance of common stock upon the exercise of warrants may be found in the company’s definitive proxy statement filed with the Securities and Exchange Commission on August 21, 2024 and available at: https://www.sec.gov/Archives/edgar/data/1411690/000114036124038087/ny20032632x2_def14a.htm
Before making any voting decisions stockholders are urged to read the company’s definitive proxy statement because it contains important information about the proposal and the Special Meeting. No changes have been made to the proposal to be voted on by stockholders at the Special Meeting.
Erik Holmlin, PhD, CEO of Bionano commented, “We are extremely grateful to our stockholders who made their voices heard through the voting process and are pleased with the voting that has occurred in the past four weeks. However, we are still short of reaching the quorum requirements for a meeting with approximately
“For this reason, we ask that you vote ‘For’ the proposal. If you have not yet voted your shares, we encourage you to vote ‘For’ the proposal. If you have voted against this proposal, you can change your vote, and we ask that you consider doing so. The failure of our stockholders to approve the proposal may materially adversely affect the Company’s future ability to raise equity or debt capital from third parties on attractive terms, if at all, and also risks significantly impairing the operations, assets and ongoing viability of the Company. As always, we are grateful to all the stockholders for their participation.”
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit www.bionano.com and www.bionanolaboratories.com .
Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “estimate,” “expect,” “may,” “plan,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the date for the reconvened meeting, and the potential negative impacts to the company if stockholders do not approve the issuance of common stock upon exercise of the warrants. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of approving the issuance of common stock upon exercise of the warrants; the impact of adverse geopolitical and macroeconomic events, such as recent and future bank failures, the ongoing Ukraine-Russia conflict, related sanctions and any global pandemics, on our business and the global economy; challenges inherent in developing, manufacturing and commercializing products; our ability to further deploy new products and applications and expand the markets for our technology platforms; our expectations and beliefs regarding future growth of the business and the markets in which we operate; changes in our strategic and commercial plans; our ability to continue as a going concern, which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; our ability to cure any deficiencies in compliance with Nasdaq Listing Rules that could adversely affect our ability to raise capital and our financial condition and business; our ability to consummate any strategic alternatives; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com
FAQ
When is Bionano's (BNGO) adjourned Special Meeting rescheduled for?
What percentage of BNGO shares voted in favor of the warrant exercise proposal?
How many additional votes does BNGO need to reach quorum?